Skip to main content
Top
Published in: Breast Cancer Research 3/2012

01-06-2012 | Review

Vitamin D and the mammary gland: a review on its role in normal development and breast cancer

Authors: Nair Lopes, Joana Paredes, José Luis Costa, Bauke Ylstra, Fernando Schmitt

Published in: Breast Cancer Research | Issue 3/2012

Login to get access

Abstract

Breast cancer is a heterogeneous disease associated with diverse biological behaviours and clinical outcome. Although some molecular subgroups of breast cancer have a targeted therapy, the most aggressive tumours still lack a molecular target. Despite vitamin D being classically associated with the physiological role of calcium regulation and phosphate transport in bone metabolism, several studies have demonstrated a wide range of functions for this hormone, which are particularly important in the field of cancer. The mechanisms underlying the protective actions of vitamin D in cancer development are only sparsely understood, but evidence shows that vitamin D participates in cell growth regulation, apoptosis and cell differentiation. In addition, it has been implicated in the suppression of cancer cell invasion, angiogenesis and metastasis. Most of vitamin D biological actions are mediated by the vitamin D receptor and the synthesis and catabolism of this hormone are regulated by the enzymes CYP27B1 and CYP24A1. In the present review we highlight research data concerning the function of this hormone in the mammary gland, with a special focus on breast carcinogenesis. Hence, and although the available data are controversial, we consider not only updated information on the epidemiology of vitamin D in breast cancer and its potential value as a therapeutic agent or prophylactic (with an emphasis on molecular mechanisms and effectors of vitamin D action), but include data on its role in other stages of breast cancer progression as well. Accordingly, we review data on the influence of vitamin D in the development of normal breast and the expression of vitamin D-related proteins (VDR, CYP27B1 and CYP24A21) in benign mammary lesions and ductal carcinomas in situ.
Appendix
Available only for authorised users
Literature
1.
go back to reference Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004, 80: 1678S-1688S.PubMed Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004, 80: 1678S-1688S.PubMed
2.
go back to reference Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998, 13: 325-349.CrossRefPubMed Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998, 13: 325-349.CrossRefPubMed
3.
4.
go back to reference Costa JL, Eijk PP, van de Wiel MA, ten Berge D, Schmitt F, Narvaez CJ, Welsh J, Ylstra B: Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics. 2009, 10: 499-CrossRefPubMedPubMedCentral Costa JL, Eijk PP, van de Wiel MA, ten Berge D, Schmitt F, Narvaez CJ, Welsh J, Ylstra B: Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down. BMC Genomics. 2009, 10: 499-CrossRefPubMedPubMedCentral
5.
go back to reference Deeb KK, Trump DL, Johnson CS: Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007, 7: 684-700.CrossRefPubMed Deeb KK, Trump DL, Johnson CS: Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007, 7: 684-700.CrossRefPubMed
6.
go back to reference Dormanen MC, Bishop JE, Hammond MW, Okamura WH, Nemere I, Norman AW: Nonnuclear effects of the steroid hormone 1 alpha,25(OH)2-vitamin D3: analogs are able to functionally differentiate between nuclear and membrane receptors. Biochem Biophys Res Commun. 1994, 201: 394-401.CrossRefPubMed Dormanen MC, Bishop JE, Hammond MW, Okamura WH, Nemere I, Norman AW: Nonnuclear effects of the steroid hormone 1 alpha,25(OH)2-vitamin D3: analogs are able to functionally differentiate between nuclear and membrane receptors. Biochem Biophys Res Commun. 1994, 201: 394-401.CrossRefPubMed
7.
go back to reference Norman AW, Bouillon R, Farach-Carson MC, Bishop JE, Zhou LX, Nemere I, Zhao J, Muralidharan KR, Okamura WH: Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem. 1993, 268: 20022-20030.PubMed Norman AW, Bouillon R, Farach-Carson MC, Bishop JE, Zhou LX, Nemere I, Zhao J, Muralidharan KR, Okamura WH: Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J Biol Chem. 1993, 268: 20022-20030.PubMed
8.
go back to reference Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW: Identification of a specific binding protein for 1 alpha,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem. 1994, 269: 23750-23756.PubMed Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW: Identification of a specific binding protein for 1 alpha,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem. 1994, 269: 23750-23756.PubMed
9.
go back to reference Zanello LP, Norman AW: Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc Natl Acad Sci USA. 2004, 101: 1589-1594.CrossRefPubMedPubMedCentral Zanello LP, Norman AW: Rapid modulation of osteoblast ion channel responses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc Natl Acad Sci USA. 2004, 101: 1589-1594.CrossRefPubMedPubMedCentral
10.
go back to reference Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW: The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol. 2004, 18: 2660-2671.CrossRefPubMed Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW: The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol. 2004, 18: 2660-2671.CrossRefPubMed
11.
go back to reference van der Rhee H, Coebergh JW, de Vries E: Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev. 2009, 18: 458-75.CrossRefPubMed van der Rhee H, Coebergh JW, de Vries E: Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev. 2009, 18: 458-75.CrossRefPubMed
12.
go back to reference Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS: Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999, 2: 283-291.CrossRefPubMed Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS: Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999, 2: 283-291.CrossRefPubMed
13.
go back to reference Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ: Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab. 1997, 82: 118-122.PubMed Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ: Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab. 1997, 82: 118-122.PubMed
14.
go back to reference Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1991-1997.CrossRefPubMed Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1991-1997.CrossRefPubMed
15.
go back to reference Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA: The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol. 2012 Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA: The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol. 2012
16.
go back to reference Rainville C, Khan Y, Tisman G: Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J. 2009, 2: 8390-CrossRefPubMedPubMedCentral Rainville C, Khan Y, Tisman G: Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J. 2009, 2: 8390-CrossRefPubMedPubMedCentral
17.
go back to reference Peppone L, Rickles A, Huston A, Sprod L, Hicks D, Mustian K, Skinner K: The association between prognostic demographic and tumor characteristics of breast carcinomas with serum 25-OH vitamin D levels. Cancer Epidemiol Biomarkers Prev. 2011, 20: 717-CrossRef Peppone L, Rickles A, Huston A, Sprod L, Hicks D, Mustian K, Skinner K: The association between prognostic demographic and tumor characteristics of breast carcinomas with serum 25-OH vitamin D levels. Cancer Epidemiol Biomarkers Prev. 2011, 20: 717-CrossRef
18.
go back to reference Anderson LN, Cotterchio M, Vieth R, Knight JA: Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr. 2010, 91: 1699-1707.CrossRefPubMed Anderson LN, Cotterchio M, Vieth R, Knight JA: Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr. 2010, 91: 1699-1707.CrossRefPubMed
19.
go back to reference Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA, Women's Health Initiative Investigators: Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008, 100: 1581-1591.CrossRefPubMedPubMedCentral Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA, Women's Health Initiative Investigators: Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008, 100: 1581-1591.CrossRefPubMedPubMedCentral
20.
go back to reference Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE: Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res. 2011, 13: R50-CrossRefPubMedPubMedCentral Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE: Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res. 2011, 13: R50-CrossRefPubMedPubMedCentral
21.
go back to reference McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE: Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009, 11: R64-CrossRefPubMedPubMedCentral McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE: Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009, 11: R64-CrossRefPubMedPubMedCentral
22.
go back to reference Zinser GM, Sundberg JP, Welsh J: Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis. 2002, 23: 2103-2109.CrossRefPubMed Zinser GM, Sundberg JP, Welsh J: Vitamin D(3) receptor ablation sensitizes skin to chemically induced tumorigenesis. Carcinogenesis. 2002, 23: 2103-2109.CrossRefPubMed
23.
go back to reference Zinser G, Packman K, Welsh J: Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development. 2002, 129: 3067-3076.PubMed Zinser G, Packman K, Welsh J: Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development. 2002, 129: 3067-3076.PubMed
24.
go back to reference Zinser GM, Welsh J: Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol. 2004, 18: 2208-2223.CrossRefPubMed Zinser GM, Welsh J: Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol. 2004, 18: 2208-2223.CrossRefPubMed
25.
go back to reference Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 1988, 67: 607-613.CrossRefPubMed Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 1988, 67: 607-613.CrossRefPubMed
26.
go back to reference Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010, 10: 483-CrossRefPubMedPubMedCentral Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010, 10: 483-CrossRefPubMedPubMedCentral
27.
go back to reference de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC, Folgueira MA: 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol. 2006, 100: 184-192.CrossRefPubMed de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC, Folgueira MA: 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol. 2006, 100: 184-192.CrossRefPubMed
28.
go back to reference Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J: Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003, 164: 239-246.CrossRefPubMed Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J: Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003, 164: 239-246.CrossRefPubMed
29.
go back to reference Segersten U, Holm PK, Bjorklund P, Hessman O, Nordgren H, Binderup L, Akerstrom G, Hellman P, Westin G: 25-Hydroxyvitamin D3 1alphahydroxylase expression in breast cancer and use of non-1alphahydroxylated vitamin D analogue. Breast Cancer Res. 2005, 7: R980-986.CrossRefPubMedPubMedCentral Segersten U, Holm PK, Bjorklund P, Hessman O, Nordgren H, Binderup L, Akerstrom G, Hellman P, Westin G: 25-Hydroxyvitamin D3 1alphahydroxylase expression in breast cancer and use of non-1alphahydroxylated vitamin D analogue. Breast Cancer Res. 2005, 7: R980-986.CrossRefPubMedPubMedCentral
30.
go back to reference Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res. 2005, 11: 3579-3586.CrossRefPubMed Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ, Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res. 2005, 11: 3579-3586.CrossRefPubMed
31.
go back to reference Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS: Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010, 57: 171-192.CrossRefPubMed Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS: Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010, 57: 171-192.CrossRefPubMed
32.
go back to reference Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J: Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001, 15: 1370-1380.PubMed Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J: Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001, 15: 1370-1380.PubMed
33.
go back to reference Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R: Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol. 1998, 142: 57-65.CrossRefPubMed Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R: Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol. 1998, 142: 57-65.CrossRefPubMed
34.
go back to reference Wu G, Fan RS, Li W, Ko TC, Brattain MG: Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene. 1997, 15: 1555-1563.CrossRefPubMed Wu G, Fan RS, Li W, Ko TC, Brattain MG: Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene. 1997, 15: 1555-1563.CrossRefPubMed
35.
go back to reference Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, Malone JM, Deppe G: Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs. 1993, 4: 201-208.CrossRefPubMed Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, Malone JM, Deppe G: Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs. 1993, 4: 201-208.CrossRefPubMed
36.
go back to reference Dhawan P, Wieder R, Christakos S: CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J Biol Chem. 2009, 284: 3086-3095.CrossRefPubMedPubMedCentral Dhawan P, Wieder R, Christakos S: CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. J Biol Chem. 2009, 284: 3086-3095.CrossRefPubMedPubMedCentral
37.
go back to reference Beildeck ME, Islam M, Shah S, Welsh J, Byers SW: Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One. 2009, 4: e7872-CrossRefPubMedPubMedCentral Beildeck ME, Islam M, Shah S, Welsh J, Byers SW: Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One. 2009, 4: e7872-CrossRefPubMedPubMedCentral
38.
go back to reference Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP: The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 2000, 19: 5091-5097.CrossRefPubMed Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP: The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 2000, 19: 5091-5097.CrossRefPubMed
39.
go back to reference Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D: Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology. 2010, 151: 32-42.CrossRefPubMed Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D: Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology. 2010, 151: 32-42.CrossRefPubMed
40.
go back to reference Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J: 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996, 58: 367-376.CrossRefPubMed Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J: 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996, 58: 367-376.CrossRefPubMed
41.
go back to reference Weitsman GE, Ravid A, Liberman UA, Koren R: Vitamin D enhances caspase-dependent and -independent TNFalpha-induced breast cancer cell death: The role of reactive oxygen species and mitochondria. Int J Cancer. 2003, 106: 178-186.CrossRefPubMed Weitsman GE, Ravid A, Liberman UA, Koren R: Vitamin D enhances caspase-dependent and -independent TNFalpha-induced breast cancer cell death: The role of reactive oxygen species and mitochondria. Int J Cancer. 2003, 106: 178-186.CrossRefPubMed
42.
go back to reference Narvaez CJ, Welsh J: Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem. 2001, 276: 9101-9107.CrossRefPubMed Narvaez CJ, Welsh J: Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem. 2001, 276: 9101-9107.CrossRefPubMed
43.
go back to reference Hoyer-Hansen M, Nordbrandt SP, Jaattela M: Autophagy as a basis for the health-promoting effects of vitamin D. Trends Mol Med. 2010, 16: 295-302.CrossRefPubMed Hoyer-Hansen M, Nordbrandt SP, Jaattela M: Autophagy as a basis for the health-promoting effects of vitamin D. Trends Mol Med. 2010, 16: 295-302.CrossRefPubMed
44.
go back to reference Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A: Vitamin D is a prooxidant in breast cancer cells. Cancer Res. 2001, 61: 1439-1444.PubMed Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A: Vitamin D is a prooxidant in breast cancer cells. Cancer Res. 2001, 61: 1439-1444.PubMed
45.
go back to reference Welsh J: Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol. 1994, 72: 537-545.CrossRefPubMed Welsh J: Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol. 1994, 72: 537-545.CrossRefPubMed
46.
go back to reference Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R: 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999, 59: 862-867.PubMed Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R: 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999, 59: 862-867.PubMed
47.
go back to reference Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R: 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 2000, 60: 2040-2048.PubMed Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R: 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res. 2000, 60: 2040-2048.PubMed
48.
go back to reference Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM: Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 1991, 51: 2848-2853.PubMed Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM: Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 1991, 51: 2848-2853.PubMed
49.
go back to reference Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V: Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 2010, 17: 273-285.CrossRefPubMedPubMedCentral Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V: Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 2010, 17: 273-285.CrossRefPubMedPubMedCentral
50.
go back to reference Hansen CM, Frandsen TL, Brunner N, Binderup L: 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis. 1994, 12: 195-202.CrossRefPubMed Hansen CM, Frandsen TL, Brunner N, Binderup L: 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis. 1994, 12: 195-202.CrossRefPubMed
51.
go back to reference Koli K, Keski-Oja J: 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000, 11: 221-229.PubMed Koli K, Keski-Oja J: 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000, 11: 221-229.PubMed
52.
go back to reference Sundaram S, Beckman MJ, Bajwa A, Wei J, Smith KM, Posner GH, Gewirtz DA: QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol Cancer Ther. 2006, 5: 2806-2814.CrossRefPubMed Sundaram S, Beckman MJ, Bajwa A, Wei J, Smith KM, Posner GH, Gewirtz DA: QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol Cancer Ther. 2006, 5: 2806-2814.CrossRefPubMed
53.
go back to reference El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R: The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000, 60: 4412-4418.PubMed El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R: The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000, 60: 4412-4418.PubMed
54.
go back to reference Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M, Munoz A: Vitamin D regulates the phenotype of human breast cancer cells. Differentiation. 2007, 75: 193-207.CrossRefPubMed Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, Gamallo C, Berciano MT, Lafarga M, Munoz A: Vitamin D regulates the phenotype of human breast cancer cells. Differentiation. 2007, 75: 193-207.CrossRefPubMed
55.
go back to reference Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, Mareel M, Bracke M, Schmitt F: P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res. 2004, 64: 8309-8317.CrossRefPubMed Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, Mareel M, Bracke M, Schmitt F: P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res. 2004, 64: 8309-8317.CrossRefPubMed
56.
go back to reference Lopes N, Carvalho J, Duraes C, Sousa B, Gomes M, Costa JL, Oliveira C, Paredes J, Schmitt F: 1Alpha,25-dihydroxyvitamin D3 Induces de novo E-cadherin Expression in Triple-negative Breast Cancer Cells by CDH1-promoter Demethylation. Anticancer Res. 2012, 32: 249-257.PubMed Lopes N, Carvalho J, Duraes C, Sousa B, Gomes M, Costa JL, Oliveira C, Paredes J, Schmitt F: 1Alpha,25-dihydroxyvitamin D3 Induces de novo E-cadherin Expression in Triple-negative Breast Cancer Cells by CDH1-promoter Demethylation. Anticancer Res. 2012, 32: 249-257.PubMed
57.
go back to reference Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T, Hiragun A: Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol. 1990, 178: 247-250.CrossRefPubMed Oikawa T, Hirotani K, Ogasawara H, Katayama T, Nakamura O, Iwaguchi T, Hiragun A: Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol. 1990, 178: 247-250.CrossRefPubMed
58.
go back to reference Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000, 87: 214-220.CrossRefPubMed Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000, 87: 214-220.CrossRefPubMed
59.
go back to reference Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A: 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 1998, 426: 225-228.CrossRefPubMed Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A: 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 1998, 426: 225-228.CrossRefPubMed
60.
go back to reference Matsumoto H, Iino Y, Koibuchi Y, Andoh T, Horii Y, Takei H, Horiguchi J, Maemura M, Yokoe T, Morishita Y: Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep. 1999, 6: 349-352.PubMed Matsumoto H, Iino Y, Koibuchi Y, Andoh T, Horii Y, Takei H, Horiguchi J, Maemura M, Yokoe T, Morishita Y: Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep. 1999, 6: 349-352.PubMed
61.
go back to reference Smeets SJ, Harjes U, van Wieringen WN, Sie D, Brakenhoff RH, Meijer GA, Ylstra B: To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic!. Clin Cancer Res. 2011, 17: 4959-4964.CrossRefPubMed Smeets SJ, Harjes U, van Wieringen WN, Sie D, Brakenhoff RH, Meijer GA, Ylstra B: To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic!. Clin Cancer Res. 2011, 17: 4959-4964.CrossRefPubMed
Metadata
Title
Vitamin D and the mammary gland: a review on its role in normal development and breast cancer
Authors
Nair Lopes
Joana Paredes
José Luis Costa
Bauke Ylstra
Fernando Schmitt
Publication date
01-06-2012
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2012
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3178

Other articles of this Issue 3/2012

Breast Cancer Research 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine